Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Aaron M Goodman, MD, Kimberly A Holden, Ah-Reum Jeong, MD, Lisa Kim, Kerry D Fitzgerald, PhD, Eyad Almasri, PhD, Graham McLennan, Marcia Eisenberg, PhD, Amin H Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, MD, Dimitrios Tzachanis, MD PhD, Edward D. Ball, MD, Taylor J Jensen, PhD BS, Razelle Kurzrock, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141010

Published: 2020

Journal Articles

Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results

Caitlin L. Costello, MD, Benjamin Brookhart, Matthew J. Wieduwilt, MD PhD, Nina Shah, MD, Carolyn Mulroney, MD, Edward D. Ball, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-143147

Published: 2020

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Safety Run-in Analysis

Caitlin L. Costello, MD, Michelle Padilla, Edward D. Ball, MD, Carolyn Mulroney, MD

Blood (2019) 134 (Supplement_1): 3117.

https://doi.org/10.1182/blood-2019-123506

Published: 2019

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Takahiro Shima, MD PhD, Amanda G Davis, Daniel T Johnson, Yu Kochi, MD, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Junichiro Yuda, MD, Toshihiro Miyamoto, MD PhD, Jie-Hua Zhou, MD, Edward D. Ball, MD, Koichi Akashi, MD PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 885.

https://doi.org/10.1182/blood-2018-99-119199

Published: 2018

Journal Articles

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Blood (2018) 132 (Supplement 1): 705.

https://doi.org/10.1182/blood-2018-99-117671

Published: 2018

Journal Articles

Comparative Inflammasome Analysis of Bone Marrow Stroma in Aging and Myelofibrosis

Larissa Balaian, PhD, Leslie A Crews, PhD, Cayla Mayson, BS, Frida Holm, PhD, Raymond H Diep, Heather Leu, BS, Anna Kulidjian, MD, Edward D. Ball, MD, Catriona Jamieson, MD PhD

Blood (2018) 132 (Supplement 1): 4331.

https://doi.org/10.1182/blood-2018-99-118993

Published: 2018

Journal Articles

CPSF1 Regulates AML1-ETO Fusion Gene Polyadenylation and Stability in t(8;21) Acute Myelogenous Leukemia

Takahiro Shima, MD PhD, Amanda G Davis, Sayuri Miyauchi, DDS, PhD, Yu Kochi, MD, Daniel T Johnson, Samuel A Stoner, BS, Yuda Junichiro, MD, Toshihiro Miyamoto, MD PhD, Jie-Hua Zhou, MD, Edward D Ball, MD, Koichi Akashi, MD PhD, Dong-Er Zhang, PhD

Blood (2017) 130 (Supplement 1): 2498.

https://doi.org/10.1182/blood.V130.Suppl_1.2498.2498

Published: 2017

Journal Articles

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 275.

https://doi.org/10.1182/blood.V130.Suppl_1.275.275

Published: 2017

Journal Articles

Decoding the RNA Editome of Normal Versus Malignant Progenitor Cell Aging Short Title: RNA Editing in Normal Aging and MDS/AML Stem Cells

Leslie A Crews, PhD, Qingfei Jiang, PhD, Larisa Balaian, PhD, Heather Leu, BS, Nathan Delos Santos, Angela C Court, Anil Sadarangani, PhD, Sheldon Morris, MD, Rainer F. Storb, MD, Anna Kulidjian, MD, Edward D. Ball, MD, Catriona Jamieson, MD PhD

Blood (2016) 128 (22): 1519.

https://doi.org/10.1182/blood.V128.22.1519.1519

Published: 2016

Journal Articles

Damage to Thymic Stroma Results in Increased Production of Pathogenic Dual Receptor T Cells Associated with Chronic Graft Versus Host Disease

Amritha Balakrishnan, Burhan Jama, Nicholas Joseph Gloude, MD, Eric Jon Anderson, MD, Edward D. Ball, MD, Gerald P Morris, MD PhD

Blood (2016) 128 (22): 1156.

https://doi.org/10.1182/blood.V128.22.1156.1156

Published: 2016

Journal Articles

A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Matthew S. Davids, MD, Haesook T. Kim, PhD, Caitlin L. Costello, MD, Peter A. McSweeney, MD, Rebecca Liguori, Alexander Lukez, David Avigan, MD, Yi-Bin Chen, MD, Nicole LeBoeuf, Vincent T. Ho, MD, Corey S Cutler, MD MPH, John Koreth, MBBS, DPhil, Edwin P. Alyea, MD, Joseph H Antin, MD, Jerome Ritz, MD, Philippe Armand, MD PhD, Edward D Ball, MD, Asad Bashey, MD PhD, Robert J. Soiffer, MD

Blood (2015) 126 (23): 860.

https://doi.org/10.1182/blood.V126.23.860.860

Published: 2015

Journal Articles

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

Leslie A Crews, PhD, Larissa Balaian, PhD, Heather Leu, BS, Nathaniel Delos Santos, Angela C Court, Anil Sadarangani, PhD, Maria A. Zipeto, PhD, James J La Clair, Reymundo Villa, Sheldon Morris, MD, Rainer F. Storb, MD, Anna Kulidjian, MD, Edward D. Ball, MD, Michael D Burkart, PhD, Catriona Jamieson, MD PhD

Blood (2015) 126 (23): 567.

https://doi.org/10.1182/blood.V126.23.567.567

Published: 2015

Journal Articles

SHH Inhibitor PF-0449913 in Vitro Remodels Leukemic Niche into HSC Supportive Niche

Larissa Balaian, PhD, Leslie C. Robertson, PhD, Anna Kulidjian, MD, Edward D. Ball, MD, Catriona Jamieson, MD PhD

Blood (2014) 124 (21): 4784.

https://doi.org/10.1182/blood.V124.21.4784.4784

Published: 2014

Journal Articles

Personalized Drug Combinations for the Treatment of Acute Myeloid Leukemia (AML) Patients

Yunyi Kang, PhD, Trish Tran, Linda Zhang, Edward D. Ball, MD, Carlo Piermarocchi, PhD, Giovanni Paternostro, MD PhD

Blood (2014) 124 (21): 3616.

https://doi.org/10.1182/blood.V124.21.3616.3616

Published: 2014

Journal Articles

A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Matthew S. Davids, MD, Haesook T. Kim, PhD, Caitlin L. Costello, MD, David Avigan, MD, Yi-Bin Chen, MD, Philippe Armand, MD PhD, Edwin P. Alyea, MD, Jacquelyn Hedlund, MD, Peter A. McSweeney, MD, Rebecca Liguori, MS, Jerome Ritz, MD, Edward D. Ball, MD, Asad Bashey, MD PhD, Robert J Soiffer, MD

Blood (2014) 124 (21): 3964.

https://doi.org/10.1182/blood.V124.21.3964.3964

Published: 2014

Journal Articles

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

Philippe Armand, MD, PhD, Waleska Perez, MPH, Mei-Jie Zhang, PhD, Haesook Kim, PhD, Thomas R. Klumpp, MD, Paola Dal Cin, PhD, Edmund K Waller, MD, PhD, Mark R. Litzow, MD, Jane L. Liesveld, MD, Hillard M. Lazarus, MD, FACP, Andrew Artz, MD, MS, Vikas Gupta, MD, MRCP, FRCPath, Bipin N. Savani, MD, Philip L. McCarthy, MD, Jean-Yves Cahn, MD, Harry Schouten, Jurgen Finke, MD, Edward D. Ball, MD, Mahmoud Aljurf, MD, Corey Cutler, MD, MPH, FRCPC, Jacob M. Rowe, Joseph H. Antin, MD, Luis M Isola, MD, Paolo Di Bartolomeo, MD, Bruce Camitta, MD, Alan M Miller, MD, PhD, Mitchell S. Cairo, MD, Keith E. Stockerl-Goldstein, MD, Jorge Sierra, MD, Mary Lynn Savoie, MD, FRCPC, Joerg Halter, MD, Patrick J Stiff, MD, Chadi Nabhan, MD, FACP, Ann A. Jakubowski, MD, PhD, Donald Bunjes, MD, Effie W. Petersdorf, MD, Steven M Devine, MD, Richard Maziarz, MD, Martin Bornhauser, MD, Victor A Lewis, MD, David I. Marks, MBBS, PHD, Christopher N Bredeson, MD, MSc, FRCPC, Robert Soiffer, MD, Daniel J. Weisdorf, MD

Blood (2010) 116 (21): 680.

https://doi.org/10.1182/blood.V116.21.680.680

Published: 2010

Journal Articles

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Edward D. Ball, MD, Bruno C. Medeiros, MD, Larissa Balaian, PhD, Tracy Roque, Sue Corringham, Richa Rajwanshi, Steven Coutre, Jason R Gotlib, MD, MS, Asad Bashey, MD, PhD, Karen Messer

Blood (2010) 116 (21): 3286.

https://doi.org/10.1182/blood.V116.21.3286.3286

Published: 2010

Journal Articles

Generation of Autologous Pre-B Acute Lymphocytic Leukemia (ALL) Reactive T Cell Lines Using ALL Blasts as Antigen Presenting Cells.

Rui-kun Zhong, MD, Thomas A. Lane, MD, Edward D Ball, MD

Blood (2009) 114 (22): 2035.

https://doi.org/10.1182/blood.V114.22.2035.2035

Published: 2009

Journal Articles

Independent and Interdependent Influence of Number of CD34+ Cells and Use of G-CSF on Outcomes in Autologous PBSCT Patients

Meghana Trivedi, PharmD, PhD, Sue Corringham, RN, Sam Martinez, PharmD, Katherine Medley, PharmD, Edward D Ball, MD

Blood (2008) 112 (11): 4319.

https://doi.org/10.1182/blood.V112.11.4319.4319

Published: 2008

NARROW

Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL

Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Safety Run-in Analysis

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Comparative Inflammasome Analysis of Bone Marrow Stroma in Aging and Myelofibrosis

CPSF1 Regulates AML1-ETO Fusion Gene Polyadenylation and Stability in t(8;21) Acute Myelogenous Leukemia

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Decoding the RNA Editome of Normal Versus Malignant Progenitor Cell Aging Short Title: RNA Editing in Normal Aging and MDS/AML Stem Cells

Damage to Thymic Stroma Results in Increased Production of Pathogenic Dual Receptor T Cells Associated with Chronic Graft Versus Host Disease

A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance

SHH Inhibitor PF-0449913 in Vitro Remodels Leukemic Niche into HSC Supportive Niche

Personalized Drug Combinations for the Treatment of Acute Myeloid Leukemia (AML) Patients

A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Generation of Autologous Pre-B Acute Lymphocytic Leukemia (ALL) Reactive T Cell Lines Using ALL Blasts as Antigen Presenting Cells.

Independent and Interdependent Influence of Number of CD34+ Cells and Use of G-CSF on Outcomes in Autologous PBSCT Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only